Back to Authors

Kumar, Shaji

https://orcid.org/0000-0001-5392-9284

A5026574827 | I1330342723

Mayo Clinic

Citations 1268

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4620-4622

10.1182/blood-2022-158231

Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4209-4210

10.1182/blood-2022-166744

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10114-10115

10.1182/blood-2022-158076

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10133-10136

10.1182/blood-2022-163555

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10142-10143

10.1182/blood-2022-169046

Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9998-9999

10.1182/blood-2022-160368

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1142-1145

10.1182/blood-2022-165524

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7315-7316

10.1182/blood-2022-164966

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7090-7091

10.1182/blood-2022-167462

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7141-7143

10.1182/blood-2022-163746